Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Avidity Biosciences Inc (NASDAQ: RNA) closed the day trading at $45.95 up 4.43% from the previous closing price of $44.00. In other words, the price has increased by $4.43 from its previous closing price. On the day, 2.36 million shares were traded. RNA stock price reached its highest trading level at $46.505 during the session, while it also had its lowest trading level at $43.46.
Ratios:
For a better understanding of RNA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.78 and its Current Ratio is at 15.78. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on September 24, 2024, initiated with a Buy rating and assigned the stock a target price of $59.
On August 28, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $63.
On May 03, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $40.BofA Securities initiated its Buy rating on May 03, 2024, with a $40 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 23 ’24 when McCarthy Teresa sold 13,153 shares for $44.00 per share. The transaction valued at 578,737 led to the insider holds 69,018 shares of the business.
Flanagan W. Michael sold 25,000 shares of RNA for $1,098,733 on Sep 23 ’24. The CSTO now owns 72,718 shares after completing the transaction at $43.95 per share. On Sep 23 ’24, another insider, Boyce Sarah, who serves as the President and CEO of the company, sold 32,880 shares for $44.00 each. As a result, the insider received 1,446,723 and left with 234,663 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 5432163328 and an Enterprise Value of 3754710272. For the stock, the TTM Price-to-Sale (P/S) ratio is 507.70 while its Price-to-Book (P/B) ratio in mrq is 4.11. Its current Enterprise Value per Revenue stands at 354.251 whereas that against EBITDA is -13.283.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $48.80, while it has fallen to a 52-week low of $4.82. The 50-Day Moving Average of the stock is 4.98%, while the 200-Day Moving Average is calculated to be 67.07%.
Shares Statistics:
Over the past 3-months, RNA traded about 1.51M shares per day on average, while over the past 10 days, RNA traded about 2515180 shares per day. A total of 117.12M shares are outstanding, with a floating share count of 108.81M. Insiders hold about 7.09% of the company’s shares, while institutions hold 93.22% stake in the company. Shares short for RNA as of 1724976000 were 10808414 with a Short Ratio of 7.92, compared to 1722384000 on 12952998. Therefore, it implies a Short% of Shares Outstanding of 10808414 and a Short% of Float of 11.3000005.
